Comparative Pharmacokinetics of Tixagevimab/Cilgavimab ( <scp>AZD7442</scp> ) Administered Intravenously Versus Intramuscularly in Symptomatic <scp>SARS‐CoV</scp> ‐2 Infection-Reference-Cited by-同舟云学术

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab ( AZD7442 ) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV ‐2 Infection

Published:2022-07-26 Issue:6 Volume:112 Page:1207-1213
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Bender Ignacio Rachel A.¹²^ORCID,Wohl David A.³^ORCID,Arends Rosalin⁴,Pilla Reddy Venkatesh⁴^ORCID,Mu Ying⁵,Javan Arzhang Cyrus⁶,Hughes Michael D.⁷,Eron Joseph J.³^ORCID,Currier Judith S.⁸^ORCID,Smith Davey⁹^ORCID,Chew Kara W.⁸^ORCID,Gibbs Michael⁴,Fletcher Courtney V.⁵^ORCID

Affiliation:

1. Division of Allergy and Infectious Diseases University of Washington Seattle Washington USA

2. Vaccine and Infectious Diseases Division Fred Hutchinson Cancer Center Seattle Washington USA

3. Institute of Global Health and Infectious Diseases University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

4. Clinical Pharmacology and Quantitative Pharmacology, Vaccines & Immunotherapies, Neuroscience and Clinical Immunogenicity AstraZeneca Cambridge UK

5. UNMC Center for Drug Discovery University of Nebraska Medical Center Omaha Nebraska USA

6. Division of AIDS National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland USA

7. Harvard T.H. Chan School of Public Health Boston Massachusetts USA

8. Division of Infectious Diseases David Geffen School of Medicine at University of California Los Angeles Los Angeles California USA

9. Division of Infectious Diseases and Global Public Health University of California – San Diego San Diego California USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2706

Reference25 articles.

1. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

2. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

3. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

4. FDA.Evusheld Healthcare Providers Factsheet: Emergency Use Authoraization for Evusheld (tixagevimab co‐packaged with cilgavimab)(2021).

5. Monoclonal antibody-based therapies for microbial diseases

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Acting Strategies for Antibody Drugs: Structural Modification, Controlling Release, and Changing the Administration Route;European Journal of Drug Metabolism and Pharmacokinetics;2024-04-18

2. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?;Viruses;2024-02-29

3. Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers;Clinical Pharmacokinetics;2023-11-13

4. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period;Frontiers in Immunology;2023-10-20

5. Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients;Transplantation;2023-07-20